Page 9 - Phasei Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

RepliCel Life Sciences, Inc.: RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor VANCOUVER, BC / ACCESSWIRE / May 17, 2021 / RepliCel Life Sciences Inc. (OTCPINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that Professor Akimichi Morita, one of Japan's leading dermatology research clinicians, has agreed to be RepliCel's clinical advisor for the development and commercialization of its skin rejuvenation product (RCS-01) in Japan. The Company,...

Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent 1 A new company-sponsored, global clinical trial will further assess berzosertib in small cell lung cancer Merck is leading more than ten clinical trials across DNA Damage Response (DDR) pathways in various tumor types Merck, a leading science and technology company, today announced key clinical advancements for berzosertib (M6620), an investigational, potent and selective ataxia telangiectasia and Rad3-related (ATR) inhibitor. Berzosertib is...

BlueRock Therapeutics to start cell therapy trial for Parkinson’s disease 8th April 2021 (Last Updated April 8th, 2021 18:15) BlueRock Therapeutics is all set to initiate Phase I Study of MSK-DA01 Cell Therapy for advanced Parkinson’s disease (PD) after it received permission from Health Canada. The trial plans to enrol ten patients in the US and Canada. Credit: National Institute on Aging, National Institutes of Health. Share Article BlueRock Therapeutics is all set to initiate Phase I Study of MSK-DA01 Cell Therapy for advanced Parkinson’...